Prostate adenocarcinoma · line 2 · Olaparib monotherapy (mCRPC, HRR-mutant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-OLAPARIB-MONO`

ID	`IND-PROSTATE-MCRPC-2L-PARPI`
Type	Indication
Status	reviewed 2026-05-07
Diseases	`DIS-PROSTATE`
Sources	`SRC-ESMO-PROSTATE-2024` `SRC-NCCN-PROSTATE-2025`

Notes

Same clinical PARPi concept as IND-PROSTATE-MCRPC-1L-PARPI, but authored as a 2L mCRPC indication so current-line rendering does not mix first-line and second-line labels. Applies when the patient is HRR/BRCA-mutant and PARPi-naive after prior mCRPC therapy.

Used By

Algorithms

ALGO-PROSTATE-MCRPC-2L - ALGO-PROSTATE-MCRPC-2L